Writing Group Disclosures.
| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Jack W. O’Sullivan | Stanford Cardiology | None | None | None | None | None | None | None |
| Pradeep Natarajan | Massachusetts General Hospital Cardiovascular Research Center | Apple†; Amgen*; Astra-Zeneca*; Boston Scientific*; Fondation Leducq†; Novartis*; NIH† (all investigator-initiated grants) | None | Allelica* | None | Named as inventors on a government-owned US patent application related to the use of genetic risk prediction for venous thromboembolic disease filed by the US Department of Veterans Affairs in accordance with federal regulatory requirements*; TenSixteen Bio†; geneXwell*; Vertex (immediate family members)† | Apple†; AstraZeneca*; Genentech/Roche†; Novartis†; Blackstone Life Sciences*; Foresite Labs†; TenSixteen Bio†; Invitae* | Massachusetts General Hospital (Paul and Phyllis Fireman Chair in Vascular Medicine)†; Vertex (medical director; immediate family members)† |
| Euan A. Ashley | Stanford University School of Medicine Center for Inherited Cardiovascular Disease | Bristol Myers Squibb (academic grant)*; Takeda (academic grant)*; Google*; Verily* | None | None | None | Personalis*; DeepCell*; Silicon Valley Exercise Analytics* | Nuevocor*; Cathay Capital (unpaid)*; Third Rock Ventures (unpaid)*; Medical Excellence*; Foresite Capital*; Novartis (unpaid)*; Samsung (unpaid)*; Analog Devices (unpaid)*; Apple†; Illumina (unpaid)*; Nanopore (unpaid)*; SequenceBio (unpaid)*; Genome Medical (unpaid)*; Disney (unpaid)* | AstraZeneca (non-executive director)* |
| Scott M. Damrauer | University of Pennsylvania School of Medicine | US Department of Veterans Affairs (genetic research on cardiovascular disease)†; Renalytix AI (precision medicine approaches to CKD progression)† | Pending patent (named as a coinventor on a government-owned US patent application related to the use of genetic risk prediction for venous thromboembolic disease filed by the US Department of Veterans Affairs in accordance with federal regulatory requirements)* | None | None | Abbott*; United Health*; Gilead*; Daiichi Sankyo*; Abbvie*; Teva* | None | None |
| Jasmine A. Luzum | University of Michigan Clinical Pharmacy College of Pharmacy | NHLBI (K08 HL146990)* | None | None | None | None | None | None |
| Carla Marquez-Luna | Icahn School of Medicine at Mount Sinai | None | None | None | None | None | None | None |
| Christopher J. O’Donnell | VA Boston Healthcare System | None | None | None | None | None | None | Novartis Institute for Biomedical Research (global head, translational medicine cardiovascular and metabolic disease)† |
| Sridharan Raghavan | Denver Veterans Affairs Medical Center | Department of Veterans Affairs (active research grant funding, including partial salary support)†; US National Institutes of Health (active research grant funding)*; Boettcher Foundation (active research grant funding, including partial salary support)† | None | None | None | None | None | None |
| Cristen J. Willer | University of Michigan Medical School | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.